BioSante Pharmaceuticals - Newsroom

2010

06/30/2010	BioSante Pharmaceuticals Announces Positive Clinical Results In Pill-Plus™ Oral Contraceptive Study
06/28/2010	BioSante Pharmaceuticals Added to Russell 3000^® Index
06/23/2010	BioSante Pharmaceuticals Closes $15 Million Registered Direct Offering to Fund LibiGel^® for Female Sexual Dysfunction
06/21/2010	BioSante Pharmaceuticals to Raise $15 Million in Registered Direct Offering
06/21/2010	BioSante Pharmaceuticals Reports Positive LibiGel^® Safety Data in Phase III Clinical Program
06/21/2010	BioSante Pharmaceuticals Says FDA Advisory Committee Recommendation Against Flibanserin has No Impact on LibiGel^®
06/18/2010	BioSante Pharmaceuticals, Inc. To Present LibiGel^® Safety Update at ENDO Annual Meeting
06/07/2010	BioSante Announces FDA Orphan Drug Designation for GVAX Chronic Myeloid Leukemia Cancer Vaccine
05/20/2010	BioSante Pharmaceuticals Announces Novartis' Successful Use of 2A/Furin Technology in Their Antibody Development Platform
05/17/2010	BioSante Pharmaceuticals Receives Two New Patents for Manufacture of Proteins, Including Antibodies
05/14/2010	BioSante Pharmaceuticals Reports Recent Developments and First Quarter Financial Results
05/12/2010	BioSante Pharmaceuticals, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
05/03/2010	BioSante Pharmaceuticals Announces Reinitiation of Prostate Cancer Vaccine Development
04/30/2010	BioSante Pharmaceuticals, Inc. to Present Cancer Vaccine Portfolio Update at the BIO International Convention
04/28/2010	BioSante Pharmaceuticals, Inc. to present at the Deutsche Bank Healthcare Conference
04/26/2010	BioSante Pharmaceuticals Enters Option Agreement to its 2A/Furin Antibody Expression Technology
04/19/2010	BioSante Pharmaceuticals, Inc. to Present and Participate in Cancer Immunotherapy Panel at the World Vaccine Congress
03/30/2010	BioSante Pharmaceuticals Reports Receipt of $2.16 Million in Elestrin™ Royalty Buydown, and Financial Results for 2009
03/23/2010	BioSante Announces Additional Positive Leukemia Vaccine Results and Second FDA Orphan Drug Designation
03/18/2010	BioSante Pharmaceuticals, Inc. and Rodman & Renshaw Announce Fireside Chat on Women's Health
03/15/2010	BioSante Announces FDA Orphan Drug Designation for GVAX Pancreatic Cancer Vaccine
03/10/2010	BioSante Announces Positive Leukemia Vaccine Results
03/09/2010	BioSante Pharmaceuticals Closes $18 Million in Registered Direct Offering
03/04/2010	BioSante Pharmaceuticals to Raise $18 Million in Registered Direct Offering
03/01/2010	BioSante Pharmaceuticals Receives Two New Patents for Manufacture of Proteins, Including Antibodies
02/22/2010	BioSante Pharmaceuticals Reports Positive LibiGel^® Safety Data in Phase III Program
02/18/2010	BioSante Pharmaceuticals, Inc. to Present LibiGel^® Clinical Update at ISSWSH Conference
02/16/2010	Sante Pharmaceuticals Rated Among Top 15 Companies on The Biotechnology Patent Scorecard™ as published in The Wall Street Journal
02/09/2010	BioSante Pharmaceuticals Appoints Jeffrey Winkelman, Ph.D., J.D., Vice President, Oncology Programs
02/08/2010	BioSante Featured on the Med Tech Sentinal
02/03/2010	BioSante Pharmaceuticals, Inc. to Present at BIO CEO & Investor Conference
01/06/2010	BioSante Pharmaceuticals, Inc. to Present at OneMedForum and Biotech Showcase Conferences

2009

2008

2007

2006

2005

12/08/2009	BioSante Pharmaceuticals Monetizes a Portion of U.S. Elestrin™ Royalties
11/17/2009	BioSante Pharmaceuticals to Present at the Lazard Capital Markets Annual Healthcare Conference
11/16/2009	BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual Dysfunction
11/10/2009	BioSante Pharmaceuticals to Present at Merriman Curhan Ford's Investor Summit
11/09/2009	BioSante Pharmaceuticals Reports Third Quarter 2009 Financial Results
10/29/2009	BioSante Pharmaceuticals to Present at the Oppenheimer Health Care Conference
10/22/2009	BioSante Pharmaceuticals to Present at the Bio Investor Forum
10/20/2009	BioSante Pharmaceuticals Reports Positive LibiGel^® Safety Data in Phase III Program
10/14/2009	BioSante Pharmaceuticals and Cell Genesys Announce Completion of Merger
09/22/2009	BioSante Pharmaceuticals and Cell Genesys Announce Final Exchange Ratio for Merger
09/03/2009	BioSante Pharmaceuticals and Cell Genesys Announce September 30, 2009 Special Stockholders Meetings to Approve Merger
09/02/2009	BioSante Pharmaceuticals to Present at Upcoming Healthcare Conferences
08/17/2009	BioSante Pharmaceuticals Reports 100% Protection From H1N1 Challenge When Using BioVant™ Adjuvanted Vaccine
08/13/2009	BioSante Pharmaceuticals to Raise $12 Million in Registered Direct Offering
08/13/2009	BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program
06/30/2009	BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement
06/29/2009	BioSante Pharmaceuticals Comments on Study Showing No Increased Risk of Breast Cancer in Women Using Testosterone for Low Libido
06/25/2009	Paper in Journal of Sexual Medicine Cites Need for FDA-Approved Testosterone Treatment to Replace Growing Off-Label Use
06/23/2009	BioSante Pharmaceuticals Announces Elestrin™ NDA Submission in Israel
06/17/2009	BioSante Pharmaceuticals LibiGel^® Safety Study to Continue Following Review by External Executive Committee
06/02/2009	BioSante Pharmaceuticals Comments on Benefits of Testosterone Use in HIV-Infected Women
05/14/2009	BioSante Pharmaceuticals to Present at The BIO International Conventio
05/11/2009	BioSante Pharmaceuticals Reports on First Quarter 2009 Financial Results and Swine Flu Activity
04/14/2009	BioSante Announces Launch of Elestrin™ in the U.S.
03/16/2009	BioSante Pharmaceuticals Reports LibiGel^® Status and Financial Results for 2008
02/17/2009	BioSante Pharmaceuticals, Inc. Presents LibiGel^® Clinical and Market Information at ISSWSH Conference
02/05/2009	BioSante Pharmaceuticals, Inc. To Present At BIO CEO and Investor Conference and ISSWSH Conference
01/05/2009	BioSante Pharmaceuticals Announces Issuance of New Patent Covering Elestrin™

12/17/2008	BioSante Pharmaceuticals Secures Committed Equity Financing Facility
12/08/2008	BioSante Pharmaceuticals Signs Elestrin™ Marketing Agreement with PharmaSwiss SA for Israel
12/04/2008	BioSante Pharmaceuticals Signs Elestrin™ Marketing Agreement with Azur Pharma
11/17/2008	BioSante Pharmaceuticals Announces Receipt of NIH Grant for Inhaled Interferon
11/11/2008	Testosterone Effective in Female Sexual Dysfunction, BioSante Conducting Long-Term Safety Study of LibiGel^® in FSD
11/10/2008	BioSante Pharmaceuticals Reports Third Quarter 2008 Financial Results
10/31/2008	Stephen M. Simes, BioSante Pharmaceuticals President and CEO, To Present At Oppenheimer and Rodman & Renshaw Conferences
10/27/2008	Stephen M. Simes, BioSante Pharmaceuticals President and CEO, To Present At The BIO Investor Forum
10/22/2008	The Only Pharmaceutical Company with A Product In Active Phase III Development for Menopausal Women Experiencing Sexual Dysfunction
09/08/2008	BioSante Pharmaceuticals Announces Positive Oral Contraceptive Clinical Results
08/11/2008	BioSante Pharmaceuticals Reports Second Quarter 2008 Developments and Financial Results
08/07/2008	BioSante Pharmaceuticals Announces Reacquisition of Elestrin™, FDA Approved for Treatment of Hot Flashes
07/24/2008	BioSante Featured on TheStreet.com TV: Stephen M. Simes, CEO, Highlights Development Program for LibiGel^®
07/16/2008	BioSante Pharmaceuticals Announces FDA Special Protocol Assessment (SPA) for Expanded Indication of LibiGel^® in FSD
06/16/2008	Stephen M. Simes, BioSante Pharmaceuticals President and CEO, To Make Two Presentations At The BIO International Convention
06/12/2008	BioSante Pharmaceuticals VP of Clinical Development To Present at The Endocrine Society's 90th Annual Meeting
06/10/2008	BioSante Pharmaceuticals Engages Deutsche Bank As Its Strategic Advisor
05/14/2008	BioSante Pharmaceuticals to Present at Two International Health Care Conferences
05/09/2008	BioSante Pharmaceuticals Reports First Quarter 2008 Financial Results
05/012008	BioSante Pharmaceuticals to Present at Deutsche Bank Health Care Conference
04/15/2008	BioSante Pharmaceuticals Appoints Michael C. Snabes, M.D., PhD, Vice President, Clinical Development
03/19/2008	BioSante Pharmaceuticals Initiates Third LibiGel^® Phase III Trial in the Treatment of Female Sexual Dysfunction under an SPA
03/17/2008	BioSante Pharmaceuticals Reports Product Development Highlights and 2007 Financial Results
03/03/2008	BioSante Pharmaceuticals to Present at the Susquehanna Healthcare Conference
02/06/2008	BioSante Pharmaceuticals to Discuss LibiGel^® SPA in the Treatment of FSD, at BIO CEO and Investor Conference
01/29/2008	BioSante Pharmaceuticals Announces FDA Special Protocol Assessment (SPA) for LibiGel^® in FSD
01/28/2008	BioSante Pharmaceuticals to Host Conference Call to Announce LibiGel^® Special Protocol Assessment (SPA)
01/15/2008	BioSante Pharmaceuticals to Ring NASDAQ Closing Bell
01/07/2008	BioSante Pharmaceuticals Announces Initiation of LibiGel^® (transdermal testosterone gel) Phase III Safety Study

12/18/2007	BioSante Pharmaceuticals Receives Milestone Payment from Bradley Pharmaceuticals
12/05/2007	BioSante Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
11/19/2007	BioSante Pharmaceuticals Announces License Agreement for its CaP Technology for Use in Aesthetic Medicinees
11/05/2007	BioSante Pharmaceuticals Common Stock Begins Trading On NASDAQ Global Market Today
11/02/2007	BioSante Pharmaceuticals Common Stock To Begin Trading On NASDAQ Global Market on Monday, November 5, 2007
11/01/2007	BioSante Pharmaceuticals Common Stock Approved for Listing on NASDAQ Global Market
10/23/2007	BioSante Pharmaceuticals Common Stock Approved for Listing on NASDAQ Global Market
10/02/2007	BioSante Pharmaceuticals to Present at Upcoming Conferences
09/17/2007	BioSante Pharmaceuticals to Present at Upcoming Conferences
09/11/2007	BioSante Pharmaceuticals Announces FDA Clarity on Development of LibiGel^® (transdermal testosterone gel) in the Treatment of Female Sexual Dysfunction
09/10/2007	BioSante Pharmaceuticals to Host Conference Call Providing LibiGel^® Clinical Development Update
09/05/2007	BioSante Pharmaceuticals Names Joy A. Thomas Vice President of Corporate Development
09/04/2007	BioSante Pharmaceuticals to Present at The Arch Investment Conference
08/14/2007	BioSante Pharmaceuticals Reports Second Quarter 2007 Financial Results
08/08/2007	BioSante Pharmaceuticals to Present at Upcoming Conferences
07/11/2007	BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
06/28/2007	BioSante Pharmaceuticals, Inc. Joins Russell Microcap Index
06/21/2007	New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, in Women aged 50-59 taking Estrogen Therapy, a Predictor of Cardiovascular Events
06/19/2007	BioSante Pharmaceuticals Announces Oral Contraceptive Phase II Study Initiation
06/14/2007	BioSante Pharmaceuticals Completes $18.3 Million Private Placement of Common Stock
06/13/2007	BioSante Pharmaceuticals Announces the Commercial Launch of Elestrin™
06/12/2007	BioSante Pharmaceuticals Announces Reinitiation of Product Development With Teva
05/30/2007	BioSante Pharmaceuticals to Present at Upcoming Conferences
05/25/2007	BioSante Pharmaceuticals Announces $16.5 Million Private Placement of Common Stock
05/16/2007	BioSante Pharmaceuticals to Present at Upcoming Conferences
05/07/2007	BioSante Pharmaceuticals Signs Oral Contraceptive License with Pantarhei Bioscience
05/02/2007	BioSante Pharmaceuticals to Present at Upcoming Conferences
05/01/2007	BioSante Pharmaceuticals Reports First Quarter 2007 Financial Results
04/10/2007	BioSante Pharmaceuticals Announces Issuance of New Patent Covering Elestrin™ and LibiGel^®
03/26/2007	BioSante Pharmaceuticals Receives Milestone Payment from Bradley Pharmaceuticals
03/09/2007	BioSante Pharmaceuticals Reports Product Development Highlights and 2006 Financial Results
03/08/2007	BioSante Pharmaceuticals to Present at Upcoming Conferences
03/08/2007	BioSante Pharmaceuticals Reports Net Profit of $2.8 million for 2006 And Investor Conference Call
03/01/2007	Lowest FDA-Approved Dosage of Estradiol to Significantly Reduce Hot Flashes Reported in Newly-Published Study
02/21/2007	BioSante Pharmaceuticals to Present LibiGel^® at International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting
02/12/2007	BioSante Pharmaceuticals Announces Presentation/Webcast at the BIO CEO & Investor Conference
02/07/2007	BioSante Pharmaceuticals Announces Notice of Allowance of ElestrinT Patent by U.S. Patent & Trademark Office
01/30/2007	BioSante Pharmaceuticals Announces Positive Bird Flu Results Using Proprietary Vaccine Adjuvant in Pre-Clinical Study

12/28/2006	BioSante Pharmaceuticals Initiates Phase III Study of LibiGel^® (transdermal testosterone gel) in the Treatment of Female Sexual Dysfunction
12/18/2006	BioSante Pharmaceuticals Receives FDA Approval of Bio-E-Gel^® (estradiol gel), to be Marketed as ElestrinT
12/04/2006	BioSante Pharmaceuticals to Present at Upcoming Biotech/Specialty Pharma and Investor Conferences
11/13/2006	BioSante Pharmaceuticals Reports Third Quarter 2006 Financial Results and Reviews Bio-E-Gel^® Marketing Agreement
11/08/2006	BioSante Pharmaceuticals Signs Bio-E-Gel^® Marketing Agreement with Bradley Pharmaceuticals, Inc
11/03/2006	BioSante Pharmaceuticals to Present at Rodman & Renshaw 8th Annual Healthcare Conference
10/16/2006	BioSante Pharmaceuticals to Present at 2006 BIO InvestorForum
10/12/2006	BioSante Pharmaceuticals Presents Bio-E-Gel^® Woman-to-Partner Transfer Study at Menopause Society Meeting
10/11/2006	BioSante Pharmaceuticals Presents Bio-E-Gel^® Data at North American Menopause Society Meeting
09/25/2006	BioSante Pharmaceuticals to Present at UBS Global Life Sciences Conference
08/14/2006	BioSante Pharmaceuticals ReportsSecond Quarter 2006 Financial Results
07/24/2006	BioSante Pharmaceuticals Closes $7.6 Million Private Placement of Common Stock
07/10/2006	BioSante Pharmaceuticals Announces $7.6 Million Private Placement of Common Stock
06/15/2006	BioSante Pharmaceuticals to Present at Needham Conference
05/12/2006	BioSante Pharmaceuticals Reports Product Development Highlights and First Quarter 2006 Financial Results
05/10/2006	BioSante Pharmaceuticals to Present Bio-E-Gel¨ and Corporate Overview at Rodman & Renshaw Global Healthcare Conference
05/08/2006	BioSante Pharmaceuticals to Present Positive Study Results for Potential Adjuvanted Bird Flu Vaccine at 9th Annual Conference on Vaccine Research
04/24/2006	BioBioSante Pharmaceuticals Announces Positive Study Resultsfor Potential Adjuvanted Bird Flu Vaccine
04/19/2006	BioSante Pharmaceuticals Announces FDA Filing and Review of NDA for Bio-E-Gel^®;
04/17/2006	BioSante Pharmaceuticals Comments on New Data from Women's Health Initiative Study Showing No Increased Risk of Breast Cancer with Estrogen-Alone Therapy
04/10/2006	BioSante Pharmaceuticals, Inc. to Present at BIO Annual International Convention on April 11 in Chicago
03/31/2006	BioSante Pharmaceuticals Reports Product Development Highlights and Financial Results for 2005
03/22/2006	BioSante Pharmaceuticals Presents New Anthrax Vaccine Data at World Vaccine Congress
03/06/2006	BioSante Pharmaceuticals to Present at International Society for the Study of Women's Sexual Health and Sachs Biotech Conferences
02/27/2006	BioSante Pharmaceuticals Signs Option and License for its CaP Technology for Use in Aesthetic Medicine
02/21/2006	BioSante Pharmaceuticals Comments on New Data from Women's Health Initiative Study Showing No Increased Coronary Heart Risk with Estrogen-Alone Therapy
02/16/2006	BioSante Pharmaceuticals Announces Bio-E-Gel^® NDA Submissione
02/13/2006	BioSante Pharmaceuticals to Participate on Panel at BIO CEO & Investor Conference
02/06/2006	BioSante Pharmaceuticals Announces Subcontract with the University of Nebraska-Lincoln Using its Proprietary CaP™ Drug Delivery System
01/09/2006	BioSante Pharmaceuticals Strengthens Management and Reaffirms Bio-E-Gel^® NDA Filing Guidance

12/12/2005	BioSante Pharmaceuticals to Present at NYSSA Biotech/Specialty Pharma Conference
12/05/2005	BioSantePharmaceuticals to Present at Informed Investors Biotechnology and Healthcare Forum
11/03/2005	BioSante Pharmaceuticals to Present at Rodman & Renshaw Techvest Healthcare Conference
11/02/2005	BioSante Pharmaceuticals Comments on Updated FDA Guidance for Testosterone Therapy
10/25/2005	BioSante Pharmaceuticals to Present Today at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference
10/18/2005	BioSante Pharmaceuticals Honors World Menopause Day
10/17/2005	BioSante Pharmaceuticals to Present at BIO InvestorForum
09/29/2005	BIOSANTE ANNOUNCES FIRST TRANSDERMAL ESTRADIOL GEL WITH 3 DOSES THAT SIGNIFICANTLY DECREASE HOT FLASHES IN MENOPAUSAL WOMEN
09/27/2005	BioSante Pharmaceuticals to Present at UBS Global Life Sciences Conference
09/21/2005	BioSante Encouraged by FDA Panel on Exubera, Superior Results of Own Inhaled Insulin Study
09/14/2005	BioSante Pharmaceuticals Signs License Option Agreement with European Pharmaceutical Company
09/13/2005	BioSante Pharmaceuticals to Present at Wall Street Reporter Small-Cap Discovery Conference
08/12/2005	BioSante Pharmaceuticals Reports Product Development Highlights and Second Quarter 2005 Financial Results
08/10/2005	BioSante Pharmaceuticals Licenses Contraceptive Technology From Wake Forest University
07/06/2005	BioSante Pharmaceuticals Announces Bio-E-Gel^® (estradiol gel) Significantly Reduces Hot Flashes in Menopausal Women
06/21/2005	BioSante Pharmaceuticals to Present at William Blair & Company Growth Stock Conference
06/16/2005	BioSante Pharmaceuticals to Present at BIO 2005 Conference
05/19/2005	BioSante Pharmaceuticals to Present at UBS Global Pharmaceuticals Conference
05/18/2005	BioSante Pharmaceuticals Presents CaP Nanotechnology Review at International Conference on Immunopotentiators in Modern Vaccines
05/16/2005	BioSante Pharmaceuticals Reports Product Development Highlights and First Quarter 2005 Financial Results
05/03/2005	BioSante Announces CaP Manufacturing Agreement and Progress in Protein Delivery
05/02/2005	BioSante Pharmaceuticals to Present at Rodman & Renshaw Techvest Global Healthcare Conference
04/19/2005	BioSante Pharmaceuticals Presents New Anthrax Vaccine Data at World Vaccine Congress
04/04/2005	BioSante Pharmaceuticals Completes Pivotal Phase III Clinical Trial for Estrogen Gel
03/30/2005	BioSante Pharmaceuticals Comments on NIH Conference Panel Statement on Estrogen Therapy for Menopausal Women
03/28/2005	BioSante Pharmaceuticals Announces 2004 Key Achievements and Financial Results
03/14/2005	BioSante Pharmaceuticals to Present at Sachs-Bloomberg Biotech Forum
02/28/2005	BioSante Pharmaceuticals to Present at Leerink Swann Healthcare Conference
02/22/2005	BioSante Pharmaceuticals Announces Panel Presentation/Webcast At the 7th Annual BIO CEO & Investor Conference
01/18/2005	BioSante Pharmaceuticals Completes Enrollment in Pivotal Phase III Clinical Trial for Estrogen Gel

News Releases